MELBOURNE, Australia and SAN FRANCISCO, April 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSA Presented additional analyses from the ATH434-201 trial demonstrating continued robust efficacy for the treatment ...
For this analysis, we grouped people into two political categories: those who support the governing political party (or parties) in each country, and those who do not. These categories were coded ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback